Long-term safety study for prior RP1, RP2, or RP3 patients
Part of Cancer, Digestive system, Skin clinical trials.
This study checks the long-term safety of patients who have already received RP1, RP2, or RP3 treatment in a previous study. It helps doctors understand any side effects that may appear over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of RP1, RP2, or RP3 in a prior study.
- You must have finished or left that prior study.
- You or your legal guardian must sign a consent form agreeing to follow the study rules.
- You must be able to follow the study visit schedule and instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.